Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Insights - 九州通 reported strong financial performance for the first three quarters of 2025, with revenue of 119.33 billion yuan, a year-on-year increase of 5.20%, and a net profit attributable to shareholders of 1.975 billion yuan, up 16.46% [1] - The company is actively implementing its "Three New and Two Digital" strategy, focusing on new products, new retail, new medical services, digitalization, and real estate securitization [1] Financial Performance - In Q3 2025, 九州通 achieved revenue of 38.22 billion yuan and a net profit of 530 million yuan, representing year-on-year growth of 5.41% and 8.46%, respectively [1] - The net profit for Q3 showed a quarter-on-quarter increase of 11.39%, while the non-recurring net profit increased by 16.49% [1] Business Development - The new product strategy has proven effective, with total brand promotion sales reaching 14.73 billion yuan in the first three quarters, driven by a 15.26% increase in pharmaceutical agency revenue [2] - The medical beauty business grew significantly, with a year-on-year increase of 45.84%, and the number of cooperative service institutions exceeding 11,500 [2] New Retail Strategy - The "Good Medicine Master" franchise plan has accelerated, with a total of 33,275 direct and franchise pharmacies by the end of Q3, and franchise store sales growing by 43.40% [2] - B2B e-commerce revenue reached 15.53 billion yuan, a year-on-year increase of 19.68%, with over 600,000 registered users on the Jiujiu platform [2] New Medical Strategy - The "Jiu Medical Clinic" membership stores exceeded 3,000, with plans to reach 10,000 in three years [3] - The introduction of over 490 new products in the supply chain has led to a 69% quarter-on-quarter increase in sales of clinic-exclusive products [3] Digitalization and REITs - 九州通 invested 229 million yuan in R&D in the first three quarters, with 1,591 technical personnel, and implemented 34 projects including AI warehouse picking and smart logistics [3] - The company's REITs project has seen a 43.28% increase since its listing, with a 100% rental rate for initial assets in Shanghai, Hangzhou, and Chongqing [3] Future Development - The chairman emphasized the commitment to deepening the "Three New and Two Digital" strategy and accelerating the development of high-margin businesses [4] - The company is exploring the replication of the REITs model for more quality warehouse assets to optimize its capital structure [4]

Core Viewpoint - 九州通's total brand promotion business (CSO) achieved a sales revenue of 14.728 billion yuan in the first three quarters of 2025, demonstrating steady growth [1] Group 1: Pharmaceutical CSO Business - The pharmaceutical CSO business generated a sales revenue of 8.740 billion yuan, reflecting a year-on-year growth of 15.26%, primarily driven by the strong performance of core products such as 可威 and 弥可保 [1] - The company has introduced 81 new product specifications during the period, including 9 high-value products, and has secured the distribution rights for 8 specifications of 卡泊三醇 in retail channels through collaboration with 利奥中国 [1] - 九州通's platforms, including 全擎健康, currently represent 783 product specifications, with 32 products achieving annual sales exceeding 100 million yuan, covering chronic diseases and anti-infection areas [1] Group 2: Medical Device CSO Business - The medical device CSO business recorded a sales revenue of 5.987 billion yuan, facing challenges due to the impact of medical consumables procurement policies on certain products like ultrasound knives and staplers [1] - The company represents 1,386 product specifications from 11 major manufacturers, including brands like 强生, 罗氏, and 雅培, across 15 product lines [1] - New product introductions, such as 登士柏 (dental) and 加奇, have shown rapid growth, with sales revenue exceeding 180 million yuan in the first three quarters [1]

Core Viewpoint - 九州通's medical device segment showed strong growth in the first three quarters of 2025, with sales revenue reaching 28.963 billion yuan, a year-on-year increase of 17.20% [1] Group 1: Business Performance - The medical device business covers three main areas: OTC, medical, and professional services, demonstrating a diversified and collaborative development pattern [1] - In the OTC segment, 九州通 collaborated with well-known brands such as Yuyue, Sanor, Kefu Mei, and Durex, achieving comprehensive coverage across all categories and channels [1] - The online business saw significant growth due to the "old-for-new" policy for consumer goods, with related sales exceeding 537 million yuan in the first three quarters [1] Group 2: Medical Business - 九州通 focuses on high-value consumables in major surgical, vascular intervention, orthopedics, and IVD fields, establishing partnerships with over 60% of the global top 100 multinational companies and 80% of domestic top 100 industrial enterprises [1] - The sales revenue from medical equipment under the "old-for-new" policy reached 5 billion yuan, marking a 42% year-on-year increase [1] - The company accelerated the expansion of its SPD (Supply Processing Distribution) business, signing 28 new projects in the first three quarters, with a cumulative total of 132 bids won [1] Group 3: Professional Services - 九州通 continues to optimize its SPD system and digital service platforms such as the Orthopedic Chang'e platform, advancing the development of SPD smart cabinets [1] - The company achieved full tracking of personnel and goods in 3D trajectories, providing integrated supply chain solutions for hospitals [1]

Core Insights - The company, Jiuzhoutong (600998), held its Q3 2025 earnings presentation on November 4, highlighting its achievements in ESG and social responsibility initiatives [1] ESG and Social Responsibility - In the first three quarters of 2025, Jiuzhoutong has actively pursued sustainable development and social responsibility, contributing a total of 17.8915 million yuan in donations and materials for energy conservation, medical assistance, and disaster relief [1] - To support the "dual carbon" goals, the company has established 30 solar power stations utilizing rooftop spaces, with a total installed capacity of 26.62 MW, and an expected annual electricity generation of 24 million kWh [1] - The company's efforts in the ESG domain have been recognized with favorable ratings from multiple institutions, including a AA rating from Wind and an A+ rating from Zhongcheng Credit Green Gold, as well as being awarded the "2025 ESG Model Enterprise" by the Golden Antelope Award, reflecting market recognition of its sustainable development achievements [1]

Core Insights - The company, Jiuzhoutong, held its Q3 2025 earnings presentation on November 4, showcasing advancements in digitalization and AI technology applications [1] Group 1: Financial Performance - In the first three quarters of 2025, the company's R&D investment reached 229 million yuan, with the number of R&D personnel increasing to 1,591 [1] Group 2: Technological Advancements - Jiuzhoutong has developed an AI intelligent system covering multiple business scenarios through independent R&D and partnerships with companies like Alibaba Cloud and Tencent Cloud [1] - The company has created several intelligent platforms, including AI+Smart Logistics, AI+Traditional Chinese and Western Medicine Diagnosis, and AI+Medical Devices [1] Group 3: Business Applications - The orthopedic Chang'e platform and Jiuyi AI-assisted diagnosis system have significantly improved efficiency in surgical instrument inventory and disease diagnosis by integrating AI technology [1] - The smart logistics system employs intelligent scheduling algorithms, enhancing the "goods-to-person" picking efficiency by 10% [1] - Jiuyi AI-assisted diagnosis platform and the internal office system "Zhi Jiugo" have integrated the DeepSeek model, while Alibaba's "Tongyi Lingma" is applied in the R&D system, effectively shortening development time and enhancing operational and decision-making efficiency [1]

Core Insights - The company has reported significant progress in its new retail strategy, particularly through the "Ten Thousand Store Franchise" initiative, which has contributed to a robust growth in sales and store expansion [1] Group 1: New Retail Strategy - The "Ten Thousand Store Franchise" strategy has led to the establishment of 33,275 direct-operated and franchised pharmacies nationwide by the end of Q3 2025 [1] - Sales revenue from franchise pharmacies reached 5.402 billion yuan, marking a year-on-year increase of 43.40% [1] - The company has expanded its supplier network to over 800 brand suppliers, enhancing its supply chain capabilities [1] Group 2: C-end Business and Services - Revenue from C-end business amounted to 2.235 billion yuan [1] - The company has over 6,800 qualified professional pharmacies, with its own pharmacies handling 429 million yuan in prescription outflow [1] - Specialized services for 13 chronic disease categories have been provided, serving over one million patients [1] Group 3: O2O Business and Digitalization - The O2O business, facilitated by the "Store Connection" system, has over 7,000 offline pharmacies for drug delivery, achieving sales exceeding 300 million yuan in the first three quarters [1] - The company offers a one-stop service for franchise pharmacies through a "Retail SaaS System + Traceability Code Solution" [1] - The digital platform, "Jiuzhou Ten Thousand Stores," serves all retail pharmacies, enhancing operational efficiency [1]

Core Insights - The core viewpoint of the article highlights the significant achievements of Jiuzhoutong's new product strategy in the first three quarters of 2025, showcasing strong sales growth and a comprehensive strategic framework [1] Group 1: Sales Performance - Jiuzhoutong's total brand promotion business, including pharmaceuticals and medical devices, achieved sales revenue of 14.728 billion yuan [1] - The pharmaceutical manufacturing and OEM business generated sales revenue of 2.3 billion yuan, reflecting a year-on-year growth of 9.93% [1] Group 2: Strategic Implementation - The company has continuously improved its new product strategy framework, establishing a complete industrial chain covering business development, research registration, product evaluation, and marketing promotion [1] - These initiatives demonstrate Jiuzhoutong's systematic approach and execution capability in new product deployment, laying a solid foundation for sustainable development [1]

（文章来源：证券日报） 本报讯天眼查App显示，近日，辽宁九州通供应链管理有限公司成立，法定代表人为刘兰芳，注册资本 2000万元，经营范围包括供应链管理服务、货物进出口、第三类医疗器械经营等。股东信息显示，该公 司由九州通医疗器械集团有限公司、沈阳越荣鑫科技服务有限公司共同持股。 ...

Group 1 - The core point of the article is the establishment of a new company, Liaoning Jiuzhoutong Supply Chain Management Co., Ltd., which is involved in supply chain management services and medical device operations [1] - The company has a registered capital of 20 million yuan [1] - The legal representative of the new company is Liu Lanfang, and it is jointly held by Jiuzhoutong Medical Device Group Co., Ltd. and other entities under Jiuzhoutong [1]